Human endogenous retrovirus tumor antigen (HERV antigen) (HERV antigen)

Human endogenous retroviruses (HERVs) are ancestral retroviral elements that comprise nearly 8% of the human genome, typically remaining transcriptionally silent in healthy somatic tissues through epigenetic repression (Nature Reviews Cancer, 2018). In various malignancies, including melanoma, breast cancer, and germ cell tumors, these sequences can be reactivated, leading to the expression of HERV-derived proteins that function as tumor-associated antigens (Frontiers in Oncology, 2020). These antigens, particularly from the HERV-K (HML-2) family, are highly specific to tumor cells, making them attractive targets for immunotherapy (Journal for ImmunoTherapy of Cancer, 2021). Therapeutic strategies currently under investigation include monoclonal antibodies, chimeric antigen receptor (CAR) T-cells, and therapeutic vaccines designed to elicit a robust immune response against HERV-expressing cells (Clinical Cancer Research, 2019). Additionally, epigenetic therapies like DNA methyltransferase inhibitors can induce “viral mimicry” by upregulating HERV expression, thereby triggering an innate immune response and sensitizing tumors to checkpoint inhibitors (Science, 2015). While promising, the development of HERV-targeted therapies must carefully account for potential cross-reactivity with physiological HERV functions, such as the role of Syncytin-1 in placental development (Cell, 2000).

Other names

HERV-derived tumor antigenEndogenous retroviral proteinHERV-K antigenHERV-W antigenHERV-H antigenRetroviral-like tumor antigen

Immunotherapy targeting HERV-expressing cells via T-cell mediated cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of viral mimicry to stimulate innate immune pathways.